Skip to content
Review Open access

Subcutaneous semaglutide and peripheral arterial occlusive disease in type 2 diabetes: network meta-analysis of randomized trials

Oct 2026 · European Heart Journal · 0 citations

Abstract

Peripheral arterial occlusive disease (PAOD) outcomes are rarely prespecified in randomised type 2 diabetes trials, limiting comparative inference across glucagon-like peptide-1 receptor agonists (GLP-1RAs). To compare GLP-1RA regimens for PAOD risk in adults with type 2 diabetes. We conducted a PRISMA-NMA systematic review and network meta-analysis. PubMed, Embase, Scopus, Web of Science, Cochrane CENTRAL, ProQuest, medRxiv, trial registries (ClinicalTrials.gov; WHO ICTRP), and Google Scholar were searched from inception to June 2025. PAOD was defined using MedDRA v26.0. Bayesian random-effects consistency NMA estimated risk ratios (RRs) with 95% credible intervals (CrIs) and ranked treatments using SUCRA. A sensitivity analysis restricted to FDA-approved, marketed agents was performed. Risk of bias was assessed using the Cochrane risk of bias-2 (ROB-2) tool. Confidence was appraised using CINeMA. Robustness was examined with frequentist random-effects NMA; inconsistency was assessed by net-splitting (direct vs indirect) and between-design Cochran’s Q. From 5,703 records, 31 randomised trials were included (11 interventions; 68,681 participants; 324 events). Semaglutide subcutaneous (SC) lowered PAOD risk versus placebo (RR: 0.38, 95% CrI: 0.14 to 0.91); no other regimen differed credibly from placebo. In active comparisons, insulin (RR: 0.22, 95% CrI: 0.04 to 0.88), semaglutide oral (PO) (RR: 0.09, 95% CrI: 0.01 to 0.87), and semaglutide SC (RR: 0.13, 95% CrI: 0.01 to 0.75) lowered risk versus a GLP-1RA+insulin combination regimen. SUCRA ranked semaglutide PO and SC as the most favourable, while GLP-1RA+insulin ranked among the least favourable and below placebo. In the FDA-approved marketed-agent sensitivity analysis (24 trials; 51,081 participants; 205 events), semaglutide SC remained protective versus placebo (RR 0.39, 95% CrI 0.14 to 0.93). CINeMA rated high confidence for semaglutide SC versus placebo and semaglutide PO versus GLP-1RA+insulin, and moderate confidence for five additional key contrasts; most other comparisons were low/very low, mainly due to imprecision. Frequentist NMA was consistent: semaglutide SC versus placebo with RR of 0.52 (95% CI: 0.29 to 0.91), with no material incoherence; rank probabilities favoured semaglutide PO/SC, and GLP-1RA+insulin was most likely worst. Heterogeneity was minimal (tau2: 0.00; I2: 0.0%, 95% CI: 0.0 to 44.6); global Q of 10.30 (p=0.989) and within-design Q of 6.31 (p=0.934). Funnel plot inspection showed no marked asymmetry. Semaglutide SC was associated with lower PAOD risk versus placebo with high confidence and robustness in a clinically relevant sensitivity analysis. Most other comparisons remain uncertain, highlighting the need for consistent PAOD endpoint capture in future trials.Figure 1 Network MapFor image description, please refer to the figure legend and surrounding text.Figure 2 League table & SUCRAFor image description, please refer to the figure legend and surrounding text.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.